2016


To access this material please log in or register

Register Authorize
2016/№1

Possibilities of Omacor in prevention of recurrent atrial fibrillation after radiofrequency ablation

Linchak R. M.1, Nedbaykin A. M.2, Komkov D. S.1, Davidenko M. N.1, Boriskina E. A.1, Sveshnikov A. S.3, Koval A. P.4, Kompaniets O. G.5, Agafonova G. A.6
1 – Federal State Budgetary Institution, “National Research Center for Preventive Medicine” of the RF Ministry of Health Care, Petroverigsky Per. 10, Bldg. 3, Moscow 101990
2 – State Autonomous Institution of Health Care, “Bryansk Region Cardiology Health center”, Oktyabrskaya 44, Bryansk 241050
3 – Federal State Budgetary Institution, “N. I. Pirogov National Medical Surgery Center” of the RF Ministry of Health Care, Nizhnyaya Pervomayskaya 70, Moscow 105203
4 – State Budgetary Institution of Health Care, “Bryansk Municipal Clinic #7”, Molodoy Gvardii 86, Bryansk 241030
5 – State Budgetary Educational Institution of Higher Professional Education,
“Kuban State Medical University” of the RF Ministry of Health Care, Sedina 4, Krasnodar 350063
6 – Municipal Institution of Health Care, “Municipal Clinic #3”, Markova 100, Armavir, Krasnodar Territory 352913

Keywords: omega-3 fatty acids, radiofrequency ablation, atrial fibrillation

DOI: 10.18087/rhj.2016.1.2163

Background. Arrhythmia recurrence is observed in every fifth or sixth patient with atrial fibrillation (AF) within a year after radiofrequency ablation (RFA), which makes increasing the RFA effectiveness a relevant objective. Aim. To study effectiveness of treatment with a ω-3 PUFA, Omacor, in different regimens for prevention of AF after RFA. Materials and methods. Three groups each containing 60 patients were formed. Group I received Omacor 2 g / day for two weeks prior to RFA followed by 1 g / day for the rest of year; group II received Omacor 1 g / day for one year; and group III (control) did not receive Omacor. Results. For the first 3–6 months, no difference between the rate of AF relapse in these three groups was observed. At 6–12 months of RFA, the relapse rate of AF in group I was significantly lower than in group III (15 % vs. 27 %, p<0.05). Conclusion. Omacor 2 g / day administered for two weeks prior to RFA with subsequent switch to 1 g / day for a year significantly reduced the relapse rate of AF in 6–12 months compared to patients not receiving the drug.
  1. Ардашев А. В., Желяков Е. Г., Долгушина Е. А., Рыбаченко М. С., Мангутов Д. А., Конев А. В. и др. Радиочастотная катетерная абляция хронической формы фибрилляции предсердий методом изоляции легочных вен и анатомической модификации субстрата аритмии. Кардиология. 2008;49 (1):39–46.
  2. Бокерия Л. А., Ревишвили А. Ш. Фибрилляция предсердий: новый подход к интервенционному и хирургическому лечению. Consilium medicum. Интервенционная кардиология. 2006;1 (3):124–9.
  3. Барсамян С. Ж., Давтян К. В., Александрова С. А., Ревишвили А. Ш. Радиочастотная аблация коллектора левых легочных вен при атипичном расположении устья ушка левого предсердия. Вестник аритмологии. 2012;68:66–8.
  4. Kosakai Y. Treatment of atrial fibrillation using the maze procedure: the Japanese experience. Semin Thorac Cardiovasc Surg. 2000 Jan;12 (1):44–52.
  5. Haissaguerre M, Shah DC, Jaïs P, Garrigue S, Takahashi A, Lavergne T et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000 Mar 28;101 (12):1409–17.
  6. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomi­zed controlled trials. Circ Arrhythm Electrophysiol. 2009 Dec;2 (6):626–33.
  7. Terasawa T, Balk EM, Chung M, Garlitski AC, Alsheikh-Ali AA, Lau J, Ip S. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med. 2009 Aug 4;151 (3):191–202.
  8. Arora S, Mookadam F, Srivathsan K. Interventional management of atrial fibrillation. Expert Rev Cardiovasc Ther. 2010 Jul;8 (7):949–58.
  9. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004 Jul 27;110 (4):368–73.
  10. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3‑polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation. 2009 Dec 8;120 (23):2315–21.
  11. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005 May 17;45 (10):1723–8.
  12. Панов А. В., Татарский Б. А., Гордеев М. Л., Нильк Р. Я. Омега-3‑полиненасыщенные жирные кислоты в профилактике фибрилляции предсердий после хирургической реваскуляризации миокарда. Рациональная фармакотерапия в кардиологии. 2008;4 (3):26–32.
  13. Синькова М. Н., Пепеляева Т. В., Исаков Л. К., Тарасов Н. И., Тепляков А. Т., Мухарлямов Ф. Ю. Отдаленные эффекты влияния омега-3 ПНЖК на течение ИБС у больных, перенесших инфаркт миокарда с подъемом сегмента ST на фоне многососудистого стенозирующего атеросклероза коронарных артерий. Сердце. 2015;14 (1):3–7.
  14. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM et al. N-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective randomized study. Circulation. 2011 Sep 6;124 (10):1100–6.
  15. Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, Horton RP et al. Omega-3 polyunsaturated Fatty Acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J. 2009 Nov 1;9 (6):292–8.
  16. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam study. Am Heart J. 2006 Apr;151 (4):857–62.
  17. Berry JD, Passman RJ, Prineas R et al. Fish and omega-3 fatty acid intake and incident atrial fibrillation: the Women’s Health Initiative. Heart Rhythm J. 2008;5 (Suppl): S22.
  18. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ et al. Fish oil and postoperative atrial fibrillation: the Omega-3 fatty acids for Prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012 Nov 21;308 (19):2001–11.
  19. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol. 2010 Mar;381 (3):1–13.
  20. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ et al. HRS / EHRA / ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Europace. 2007 Jun;9 (6):335–79.
  21. Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol. 2013 Jan 29;61 (4):463–8.
  22. Boland LM, Drzewiecki MM. Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem Biophys. 2008;52 (2):59–84.
  23. Xiao YF, Ke Q, Chen Y, Morgan JP, Leaf A. Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+ / Ca2+ exchange current in HEK293t cells. Biochem Biophys Res Commun. 2004 Aug 13;321 (1):116–23.
Linchak R. M., Nedbaykin A. M., Komkov D. S., Davidenko M. N., Boriskina E. A., Sveshnikov A. S. et al. Possibilities of Omacor in prevention of recurrent atrial fibrillation after radiofrequency ablation. Russian Heart Journal. 2016;15 (1):34–39

To access this material please log in or register

Register Authorize
Ru En